Pd-1 Antibody Combined Neoadjuvant Chemotherapy for Locally Advanced Cervical Cancer

Cervical cancer is one of the major health problems for chinese women. Besides surgery and radiotherapy, neoadjuvant chemotherapy has been proved to be an effective program by many studies. However, not all patients respond well to neoadjuvant chemotherapy. This is an open-label, single-arm, multi-center clinical trial to evaluate whether PD-1 in combination with neoadjuvant chemotherapy will achieve better objective response rate.

NCT Number	NCT04516616
Lead Sponsor	Huazhong University of Science and Technology Collaborators: Women's Hospital School Of Medicine Zhejiang University, Qilu Hospital of Shandong University, Obstetrics & Gynecology Hospital of Fudan University, First Affiliated Hospital of Chongqing Medical University, Army Medical University, China, Peking University People's Hospital, Tianjin Medical University General Hospital, The Second Affiliated Hospital of Harbin Medical University, Chongqing University Cancer Hospital, The First Affiliated Hospital of China University of Science and Technology (Anhui Provincial)
Conditions	Uterine Cervical Neoplasm, Uterine Cervical Cancer, Cervical Cancer
Enrollment	85 participants
Start Date	2020-12-01
Primary Completion	2023-04-30 (estimated)
Study Completion	2028-07-01 (estimated)
Updated on ClinicalTrials.gov	2025-03-20